The 2023 San Antonio Breast Cancer Symposium (SABCS) meeting was held December 5-9, 2023 in San Antonio, TX and virtually. Click the links below to read about MBC research reported at this meeting. See also the videos we highlight in this month’s From the Experts post: Experts Break Down Important MBC Research from SABCS 2023.
HR+ MBC
- Breastcancer.org: Inavolisib, an alternative treatment to alpelisib (Piqray®), may work better with fewer side effects for hormone receptor-positive MBC with a PIK3CA mutation
- Medsir: Letrozole (Femara®) and fulvestrant (Faslodex®) worked equally well when combined with palbociclib (Ibrance®) for hormone receptor-positive MBC
- Medsir: Circulating tumor DNA in a liquid biopsy may be useful to identify the best type of hormone therapy in hormone receptor-positive MBC
HER2+ MBC
- Breastcancer.org: Adding tucatinib (Tukysa®) to ado-trastuzumab emtansine (T-DM1; Kadcyla®) improved survival in people with HER2-positive MBC, including people with brain metastases, compared to only T-DM1
- Med Page Today: The bispecific antibody zanidatamab plus palbociclib (Ibrance®) and fulvestrant (Faslodex®) provided 1 year of progression-free survival for hormone receptor-positive, HER2-positive MBC
Triple-Negative MBC
Lobular Breast Cancer
- SABCS (video): Imaging for metastatic lobular breast cancer and the importance of including people with lobular breast cancer in clinical trials
Antibody-Drug Conjugates (ADCs)
- Living Beyond Breast Cancer: The ADC, datopotamab deruxtecan (Dato-DXd), provides better progression-free survival and fewer side effects than chemotherapy for hormone receptor-positive, HER2-negative MBC that is resistant to hormone therapy
Quality of Life
- Living Beyond Breast Cancer: Exercise improves quality of life and physical fitness in people with MBC
- Unite for HER: People living with breast cancer, including MBC, who received eating and nutrition support reported lower depression, anxiety, and pain that interfered with enjoyment of and participation in life, and higher physical function than those who did not receive this support